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mulation of mutations may lead to acceleration of tumor
development and to presentation of breast cancer at a
much earlier age. The normal lifetime risk of developing
breast cancer in HNPCC patients may indicate that the
MMR defect is not involved in the initiation of breast
cancer.
The answer to the question whether breast cancer is
part of the tumor spectrum of HNPCC should be “no”
if we consider the absence of an increased lifetime risk.
Yet this question should be answered with “yes” if we
take into account the possible role of the MMR defect
in the progression of a breast tumor. Application of the
latter criterion implies that a large variety of tumor types
should in fact be regarded as part of the tumor spectrum
of HNPCC. We believe that decisions as to whether sur-
veillance should be advised for a specific type of cancer
should be based on the age-specific cancer risk and the
availability of sensitive and specific screening tools.
Many cancers that are currently not included in the sur-
veillance programmay develop at an early age in patients
with HNPCC. Therefore, we urge clinicians managing
HNPCC to be especially alert when the patient presents
with unusual symptoms.
H. F. A. VASEN,1 H. MORREAU,2
AND J. W. R. NORTIER1
Departments of 1Clinical Oncology and 2Pathology
Leiden University Medical Center
Leiden, The Netherlands
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Reply to Vasen et al.
To the Editor:
Hereditary nonpolyposis colorectal cancer (HNPCC) is
associated, at least in part, with germline mutations in
genes involved in DNA mismatch repair. Two genes,
termed “hMSH2” and “hMLH1,” account for HNPCC
in ∼60% of families whose symptoms adhere to the
Amsterdam Criteria (Syngal et al. 2000). Three other
genes—hPMS1, hPMS2, and hMSH6—account for an
additional 5%–10%, the exact percentage not being
known at this time. There remains a significant pro-
portion of families, ∼30%, in which HNPCC does not
appear to be accounted for by these genes, suggesting
that additional genes, which may or may not have any-
thing to do with DNA mismatch repair, are involved.
Given that errors in DNA mismatch repair result in the
characteristic signature of microsatellite instability
(MSI), it should be relatively straightforward to deter-
mine whether families whose symptoms adhere to the
Amsterdam Criteria but who do not harbor changes in
known DNAmismatch-repair genes displayMSI. To our
knowledge, little information exists that indicates which
of these two scenarios is most likely.
The letter by Vasen et al. (2001) questions the asso-
ciation between mutations in the DNA mismatch-repair
gene hMLH1 and breast cancer, which we identified in
a report published at the beginning of this year (Scott
et al. 2001). In our report, we presented data that in-
dicated a statistically significant difference between the
likelihood of developing breast cancer in the hMLH1
mutation–positive group and the mutation-negative
group compared with the likelihood in hMSH2 muta-
tion–positive families. One of the reasons we focused on
breast cancer was precisely because there was little or
no agreement as to whether it was part of the disease
spectrum of HNPCC. Furthermore, there were sufficient
anecdotal reports of breast cancer occurring at an earlier
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age within the context of HNPCC to suggest that it is
part of the disease spectrum.
The results that were obtained reflect breast cancer
incidence observed in our population.We cannot explain
why the findings for our population differ from those
observed in the Dutch families with HNPCC or those
reported by Watson et al. (1993) or Aarnio et al. (1999),
who showed that there was no increased risk of breast
cancer in HNPCC. In the analysis of Dutch families
with HNPCC, either no association or indeed a slight
protective effect of DNA mismatch-repair errors was
reported.
There are several interesting differences between our
population and the Dutch population. The most inter-
esting is the relative percentage of families with linkage
to hMSH2 and hMLH1. In Holland, the ratio of hMSH2
to hMLH1 mutation carriers is ∼1:1, compared with
our findings, which suggest a 1:2 ratio of hMSH2 to
hMLH1 mutations. This difference does not account for
the discrepancy seen between our population and the
Dutch population, but it does suggests that there are
significant differences between the two. We are currently
accumulating more HNPCC families (1230) and will re-
analyze the data when mutation analysis is complete, to
determine whether the results of our initial analysis of
the first 95 families hold true or were a result of a bias
within our population.
Finally, we agree with the notion put forward byVasen
et al. (2001) that breast cancer development may be
accelerated in persons who are deficient in DNA mis-
match repair.
RODNEY J. SCOTT
Discipline of Medical Genetics
Faculty of Medicine and Health Sciences
University of Newcastle
New Lambton, New South Wales
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Mitochondria and the Quality of Human Gametes
To the Editor:
Ruiz-Pesini et al. (2000) cleverly show that extant hu-
man mtDNA variation affects sperm function. They find
that mitochondrial haplogroup T is overrepresented in
asthenozoospermic populations and shows reduced
sperm oxidative phosphorylation pathway (OXPHOS)
activity, relative to the H haplogroup that is over-
represented in nonasthenozoospermic populations.
These authors—as well as Moore and Reijo-Pera (2000),
in the accompanying invited editorial—stress that, be-
cause of the exclusive matrilinear inheritance of mito-
chondria, mutations of mtDNA purely affecting male
fertility are not selected against and therefore can be-
come fixed. The absence of a direct check against mi-
tochondrial mutations that affect male fertility is un-
fortunate and begs the question of why such a pattern
became established.
In keeping with an earlier suggestion (Giannelli 1986),
I propose that the exclusion of spermmitochondria from
the zygote is part of a scheme enabling mitochondria to
provide an indirect measure of sperm quality and, hence,
to favor fertilization by optimal spermatozoa while
avoiding the risk of passing on mtDNA exposed to
high physiological stress and, hence, potential damage.
This would clearly have adaptive value and could help
justify the establishment of matrilineal mitochondrial
inheritance.
There is evidence that mitochondria have a role in
germ-cell selection. Krakauer and Mira (1999), in a
phylogenetic study, note that species producing fewer
offspring have fewer egg mitochondria and experience
greater ovarian atresia, and these authors conclude that
lower numbers of mitochondria offer greater opportu-
nities for variation in mitochondrial function and, thus,
for elimination of eggs with poor mitochondria. This
results in purifying selective pressure on mitochondrial
genomes. Some proof of a mitochondrial role in ovarian
